

*Afr. J. Trad. CAM* (2006) **3** (4): 102 - 114



**Research Paper**

**ISSN 0189-6016©2006**

*Afr. J. Traditional,  
Complementary and  
Alternative Medicines*  
[www.africanethnomedicines.net](http://www.africanethnomedicines.net)

## **RAPID *IN VIVO* SCREENING METHOD FOR THE EVALUATION OF NEW ANTI *HELICOBACTER* MEDICINAL PREPARATIONS**

**Maurice Boda\*, Paul V. Tan\*\*, Barthelemy Nyasse\$.**

\*\* Department of Animal Biology & Physiology, Faculty of Science, Box 812, University of Yaounde I, Cameroon, \*Department of Biochemistry, Faculty of Science, Box 812, University of Yaounde I, Cameroon, \$Department of Organic Chemistry, Faculty of Science, Box 812, University of Yaounde I, Cameroon

**E-mail:** \*\*[pvernyuy@yahoo.com](mailto:pvernyuy@yahoo.com), Tel: 237 775 65 84.

## **Abstract**

The objective of this study was to devise a rapid mouse model for the *in vivo* screening of new anti *Helicobacter pylori* products. Six to eight week-old mice pre-treated (7 days) with Amoxicillin/Metronidazole (25 mg/kg) to eliminate all *Helicobacter*-like organisms were inoculated (4x per week) with 200 µl of a bacterial culture ( $10^8$  CFU/ml of *H. pylori* CCUG-39500). Colonisation of mouse stomach was assessed from day 1 to 15 post inoculation by the Gram stain, rapid urease test and antral mucus culture. These findings were used as a mouse model of *Helicobacter pylori* infection to assess the *in vivo* anti *Helicobacter* activities of two plant-derived molecules with proven cytoprotective, ulcer healing and *in vitro* anti *Helicobacter* properties (TN, a tabersonine chloride alkaloid from the fruits of *Voacanga Africana* and **PAL**, a protoberberine alkaloid ((7,8-dihydro-8-hydroxy-palmatine) from the bark of *Enantia chlorantha*). For up to 6 days post inoculation, the test organisms were recoverable by culture from 87.5% of the antral mucus samples while 100% of Gram stains were positive. The infection tended to clear naturally from day 9. Fifteen days post infection, only Gram stains were still positive (37.5%). Three-day oral administration of TN, PAL (50 mg/kg) and Metronidazole (25 mg/kg) completely eliminated the bacterial strain from the gastric antral mucus compared with the controls. This 4-week model is proposed as a rapid screening tool for *in vivo* evaluation of new anti *H. pylori* products in order to select candidates for detailed investigations.

**Keywords:** *Helicobacter pylori*, *in vivo*, mouse model.

## **Introduction**

*Helicobacter pylori* (*H. pylori*), has probably been part of the human gastric biota since time immemorial (Blaser, 1997), but its implication in chronic gastritis, peptic ulcer disease, gastric cancer as well as mucosa-associated lymphoid tissue (MALT) lymphoma has made it a major public health concern (DeCross and Marshall,

1993; Graham, 1997; Gibson et al., 1999) since these diseases are major causes of death worldwide (Radcliff et al., 1996). Genetic diversity between clinical isolates from different populations is one of the most distinctive characteristics of this pathogen (Niyaz and Sechi, 2005). These findings have considerably revolutionized the management of peptic ulcer disease and gastroduodenal malignancies. *H. pylori* eradication is now a major step in the therapeutic management of these diseases (Walsh, 1995; Beales, 2001), and effective treatment of *H. pylori*-induced peptic ulcer disease requires the use of at least two antimicrobial agents (selected among Amoxicillin, Metronidazole, Clarithromycin and Tetracycline) combined with antacids and/or antisecretory agents (Hentschel et al., 1993; Dunn et al., 1997; Beales, 2001; Kanamaru et al., 2001). The Emergence of *H. pylori* strains resistant to the recommended antibiotics, the associated side effects and low patient compliance, are cited as some of the major causes of treatment failure (Skirrow, 1992; Fauchère, 1999; Kato et al., 2000; Okamoto, 2002). Developing new anti-*Helicobacter* compounds is therefore of great importance.

The literature is rich with information on the *in vitro* assessment of anti-*Helicobacter* properties of medicinal plant products (Nataliya et al. 2000; Yee and Koo, 2000; Kanamaru et al., 2001; Marone et al., 2001; Mahady et al., 2003a; Mahady et al., 2003b). However, the therapeutic usefulness of products active *in vitro* must be confirmed by *in vivo* tests. Although no animal model of *H. pylori* infection exactly mimics the human disease, experimental animal models using primates, domestic cats and dogs, gnotobiotic piglets, ferrets, Mongolian gerbils and mice have provided important insights into the *in vivo* evaluation of new antimicrobials. This has increased the understanding of host-pathogen relationships and virulence factors of the various strains of *H. pylori* (Danon et al. 1995; Enno et al., 1995; Fox et al., 1995; Sakigami et al., 1996; Lee et al., 1997; Lee, 1998; Krakowka et al., 1998; Kanamaru et al., 2001; Sgouras et al., 2004). The use of large animals is cumbersome and time-consuming but also very expensive and therefore available only to few investigators. Mouse-based *H. pylori* infection models are very useful tools, and for studies to be comparable between laboratories, standard criteria (the 1995 Lausanne criteria) were agreed upon. The Sydney strain of *H. pylori* (SS1) has been used successfully for the study of *H. pylori* pathogenesis, vaccine development and for the screening of anti *H. pylori* products (Lee et al., 1997; Lee, 1998; Jenks et al., 1999; Sizemore et al., 2002; Loughlin et al., 2003; Sgouras et al., 2004).

Short stomach transit time and poor acid stability render many compounds endowed with *in vitro* anti-*Helicobacter* properties ineffective *in vivo* (Haas et al., 1990; Skirrow, 1992; Krakowka et al., 1998). Although, according to the Lausanne criteria, permanent colonisation leading to pathology is a pre-requisite for animal models designed to assess host-pathogen relationships and microbial eradication in well-established *H. pylori*-induced disease conditions, this may not necessarily be the case when the experimental goal is to screen large numbers of new products for *in vivo* anti *Helicobacter* activity. In many developing countries, the lack of experimental facilities usually hamper the effort of scientists working in this domain. For these reasons, we have designed a short-term (two-week) *in vivo* mouse model that can be used for the screening of new anti *H. pylori* products prior to the selection of candidates for more detailed expensive experimentation. This study describes a simplified *in vivo* method for assessing the anti-*Helicobacter* activity of compounds using the easily-

cultured CCUG-39500 *H. pylori* strain in mice. The paper describes the preparation of *H. pylori*-free mice, the preparation and maintenance of *H. pylori* bacterial culture, confirmation of effective infection of mice with the *H. pylori* strain and the subsequent eradication of the microbes using two test compounds and a standard control drug.

## Materials and methods

### Plant materials

The alkaloid (7,8-dihydro-8-hydroxy-palmatine) prepared from *Enantia chlorantha* Oliver, Annonaceae (voucher specimen N° 25918/SRFCAM) was used. (Figure 1). The bark was collected from Edea in the Littoral Province of Cameroon. The extraction, isolation and purification of the active compound were done as previously reported (Tan et al., 2000). A more detailed report is presented by Wafo et al. (1999). The compound was code named **PAL**. The purified compound prepared from the fruits of *Voacanga africana* Stapf (Apocynaceae) is an alkaloid (TN) with Cameroon National Herbarium voucher specimen N° HNC/ 1949: P. Nana. The fruits were harvested in Yaoundé, sun dried and ground to a powder. Detailed preparation procedure for TN is reported by Tan and Nyasse (2000). Preliminary chemical and physical data suggested that the compound may correspond to tabersonine hydrochloride (m.p.192-195;  $[K]_D$  -307; elemental analysis:  $C_{20}H_{26}O_2N_2 \cdot HCl$ ) and its detailed structural elucidation awaits publication.

### Animals

Six to eight-week old inbred healthy Swiss mice weighing between 17 and 23 g were used for the study. To avoid coprophagy, they were housed in raised wire mesh bottom cages. The animals were maintained on a 12 h light/dark cycle with water *ad libitum*, and fed with laboratory baked food made of maize (50%), soybeans (25%) and wheat flour (25%), supplemented with table salt, palm oil, fish and bone powder. Prior authorization for the use of laboratory animals was obtained from the Cameroon National Ethics Committee (Reg. No. FWA-IRB00001954).

### Culture media, and culture media supplements

Columbia agar (CM0331), Brain Heart Infusion (CM0225), Lacked Horse Blood (SR0048), Horse Serum (SR0035), Vitox supplement (SR0090), *Helicobacter pylori* DENT supplement (SR0147) as well as the CampyGen gas pack (CN0024A) were all purchased from Oxoid, Basingstoke, England.

### The microbial strain

Lyophilised *Helicobacter pylori* CCUG 39500 was obtained from the Culture

Collection University of Göteborg (CCUG), Sweden. The strain was revived using Brain Heart Infusion supplemented with 10% horse serum (BHI-serum) and identified using the rapid urease and the catalase/oxydase tests (Fauchere, 1999; Dunn et al, 1997). It was maintained under microaerophilic conditions at 37°C on Columbia agar supplemented with 5% (v/v) lacked horse blood and 1% (v/v) Vitox, and subcultured every 96 hours to a fresh medium. The microaerophilic conditions were generated using CampyGen in a 2.5 L air-tight anaerobic jar (Oxoid). The isolation of *H. pylori* from mouse stomach biopsies was done on Columbia-DENT agar supplemented with 5% (v/v) lacked horse blood and 1% (v/v) Vitox (CD-Vitox). The infective inoculum was prepared by suspending 72-h colonies in 2 ml of sterile normal saline to make a turbidity standard of McFairland N° 1. The cell suspension of this turbidity standard was evaluated by standard plate count and was found to vary from  $1.60 \times 10^8$  to  $3.05 \times 10^8$  CFU/ml (Cheesbrough, 1985).

### **Antibiotics**

Amoxicillin (Amoxyl 500 mg/5 ml) and Metronidazole (Metronidazole USP RTU®; 500 mg/100 ml) purchased from a local pharmacy were, respectively, from GlaxoSmithKline Australia Pty Ltd. and Baxter Healthcare Corporation, Deerfield. Stock solutions were prepared. The concentrations used in mice were prepared using sterile normal saline.

### **Eradication of *Helicobacter*-like organisms.**

In order to ensure that the mice used were free from other *Helicobacter*-like organisms (HLOs), they were pre-treated with a mixture of Amoxicillin (25 mg/kg) and Metronidazole (25 mg/kg) administered *per os* once daily for seven consecutive days in a final volume of 200 µl. A preliminary experiment was conducted on 20 animals grouped as follows: a test group (5 females and 5 males) treated for seven days with the HLO eradication regiment and a control group (5 females and 5 males) treated for 7 days with 200 µl of sterile normal saline (NaCl 0.9 %). The animals were fasted on the 8<sup>th</sup> day after which they were sacrificed. The stomachs were removed and the antral mucus layer was scraped. Part was used to prepare Gram stain slides and part was inoculated in urea broth while the remainder was homogenised in a test tube containing 500 µl of BHI. The homogenate was inoculated by flooding on CA-Vitox -DENT plate. The plate was incubated under microaerophilic conditions for five days before discarding. The urea broth was incubated in a candle jar for 3 hours after which the tubes were observed for any colour change. The Gram stain, urease test and culture technique did not reveal the presence of HLOs in both the test and control groups. Thus, the antibiotic pre-treatment satisfactorily certified the animals as *helicobacter*-free.

### **Infection of mice with *H. pylori* CCUG-39500 and assessment of colonisation**

Forty-eight mice *Helicobacter*-free mice (24 males and 24 females) were allowed to rest for a further 7 days in order to clear the system of circulating

antibiotics. Following a 12-h fast, the mice were inoculated *per os* with 200 µl of bacterial culture containing  $10^8$  CFU/ml of *H. pylori* CCUG-39500. The inoculation was done four times a week, with a 24-h interval between inoculations. Each inoculation was preceded by a 12-h fast. In order to confirm effective infection, six groups of 8 mice each (4 males and 4 females) were sacrificed respectively on days 1, 3, 6, 9, 12, and 15 following the last inoculation. *H. pylori* colonisation was assessed by Gram staining, rapid urease activity, and culturing of samples of the mucus layer of the antrum as described above. Positive cultures were further confirmed with the urease, catalase and oxydase tests.

### **Assessment of *H. pylori* eradication.**

Mice (8 per group) infected as described above, were allowed to rest for a day after the last inoculation. They were then given the test products orally, once daily for three consecutive days. The plant preparations were administered in a final volume of 500 µl of 0.25% Tween 80 at the dose of 50 mg/kg. A positive control group was treated with Metronidazole (25 mg/kg) and a negative control group was given 500 µl of a sterile solution of 0.25% Tween 80. Following the last day of antibiotic treatment, the mice were fasted for 12 h after which they were sacrificed. The stomachs were excised and *H. pylori* clearance was assessed by Gram staining, rapid urease test and culture as described above.

## **Results**

### **Assessment of *H. pylori* CCUG-39500 infection of the mice**

In order to make sure that the animals used for the experiment were *Helicobacter*-free, all were pre-treated with an eradication regimen (Amoxicillin and Metronidazole) before infection with the experimental strain of *H. pylori*. The assessment of evidence of colonisation with *H. pylori* CCUG-39500 was simultaneously done by Gram staining, and the rapid urease test and culture for isolation of viable *H. pylori*. A slight change in the colour of the urease test tube within 3 hours was considered as positive. Some of the tubes showed a clear pink colour after 1 to 2 h but in some tubes a pale pink colour could be observed after three hours. There was therefore variation in the speed and the intensity of the urease reaction. From the 1<sup>st</sup> to the 6<sup>th</sup> day, evidence of colonisation was demonstrated by the Gram stain, rapid urease test and the culture technique (Table 1). The infection began to clear from the stomachs of 5 out of the 8 animals 9 days after inoculation with the bacterial culture. This was shown by negative cultures and urease tests. However, the Gram staining technique still revealed the presence of curved Gram negative bacteria in the smears prepared from the stomachs of all the group 4 animals sacrificed on day 9. Although the Gram stain continued to reveal the presence of infection in 5 to 6 animals (62.5 – 75%) up to day 15, the urease test and culture plates did not reveal signs of infection as of day 12 post inoculation. No apparent differences were noticed between male and female mice in infectivity with the microbe or onset of clearance from the stomachs.

Table 1: Assessment of the presence of *H. pylori* in the mouse stomach after infection with *H. pylori* CCUG–39500

		Day 1 (Group 1)			Day 3 (Group 2)			Day 6 (Group 3)			Day 9 (Group 4)			Day 12 (Group 5)			Day 15 (Group 6)		
		G	U	C	G	U	C	G	U	C	G	U	C	G	U	C	G	U	C
Animal N°	1	+	+	+	+	+	+	+	+	+	+	+	–	+	–	–	+	–	–
	2	+	+	+	+	+	+	+	+	+	+	+	+	+	–	–	+	–	–
	3	+	+	+	+	+	+	+	+	+	+	+	+	+	–	–	+	–	–
	4	+	+	+	+	+	+	+	+	+	+	+	–	–	–	–	–	–	–
	5	+	+	+	+	+	+	+	+	–	+	–	–	+	–	–	+	–	–
	6	+	+	+	+	+	+	+	+	+	+	–	–	–	–	–	–	–	–
	7	+	+	+	+	+	+	+	+	+	+	+	+	+	+	–	+	–	–
	8	+	+	+	+	+	+	+	+	+	+	+	–	+	–	–	–	–	–
% positive		100	100	100	100	100	100	100	87.5	87.5	100	75	37.5	62.5	12.5	00	62.5	00	00

G: Gram staining

U: Rapid Urease test

C: Culture

+: positive test or reaction

–: Negative test or reaction

Animals: No.1 to 4 are males; No. 5 to 8 are females. Group 1-6 animals were sacrificed on day 1, 3, 6, 9, 12 and 15, respectively, post infection.

### ***In vivo* eradication of *H. pylori* CCUG-39500 in mice**

This assay was done in order to assess the ability of compounds with proven *in vitro* *H. pylori* activities to rid the stomach antrum of *H. pylori* following *in vivo* treatment. All the animals in the negative control group were successfully infected with *H. pylori* throughout the test period and the treatment with 0.25% (v/v). Tween 80, 500µl daily did not eradicate the pathogen (Table 2, Plate 1). In contrast, the cultures of the gastric tissue samples from the infected mice treated with PAL and TN as well as Metronidazole did not yield any growth after three days of treatment (Table 2; Plates 2 - 4). In the group treated with TN, the Gram stain, the rapid urease test, as well as the tissue cultures were negative for all the 8 animals. Positive Gram stains were obtained in one case for PAL and in two cases for Metronidazole.

## **Discussion**

Studies on the ecology of *Helicobacter* have proposed that various animal species harbour specific *Helicobacter* species. Thus, *H. pylori*, *H. felis*, *H. mustelae*, and *H. heilmannii* are species adapted to man, cats/dogs, ferrets and primates,

Table 2: Assessment of *H. pylori* clearance from mouse stomach following three days of treatment with TN, PAL and metronidazole.

	PAL 50 mg/kg BW			TN 50 mg/kg BW			Metronidazole 25 mg/kg BW			Control (0.25% (v/v) Tween 80)		
	G	U	C	G	U	C	G	U	C	G	U	C
1	–	–	–	–	–	–	–	–	–	+	+	+
2	–	–	–	–	–	–	–	–	–	+	+	+
3	–	–	–	–	–	–	–	–	–	+	+	+
4	–	–	–	–	–	–	–	–	–	+	+	+
5	+	–	–	–	–	–	–	–	–	+	+	+
6	–	–	–	–	–	–	+	–	–	+	+	+
7	–	–	–	–	–	–	–	–	–	+	+	+
8	–	–	–	–	–	–	+	–	–	+	+	+
% Negative	87.5	100	100	100	100	100	75	100	100	0	0	14

G: Gram stain

U: Rapid Urease test

C: Culture

+: positive test or reaction

–: Negative test or reaction

Animals: No.1 to 4 are males; No. 5 to 8 are females.





Figure 1: Chemical structure of PAL (7,8-dihydro-8-hydroxy-palmatine)


respectively. (Stephen Danon et al., 1995). This notwithstanding, primates have been known to become infected with *H. pylori*, mouse models of *H. felis* which mimic the human pathology have been developed, a colony of SPF cats has been infected with a *H. pylori* isolate, and *H. heilmannii* is also known to be a natural feline *Helicobacter* ( Lee, 1998; Enno et al., 1995; Lee et al., 1990). Although early studies showed that mice could not be infected by clinical isolates of *H. pylori*, Lee et al. (1997) quickly developed a mouse model using a human clinical isolate, the “Sydney strain” of *H.*




**Plate 1:** Photograph of a positive Gram stain of the control mucous layer, after treatment for three days with 0.25% (v/v) Tween 80. Arrows indicate the Gram negative curved bacteria (*H. pylori*).



**Plate 2:** Photograph of a negative Gram stain of the mucous layer, after treatment for three days with Metronidazole (25 mg/kg body).



**Plate 3:** Photograph of a negative Gram stain of the mucous layer, after treatment three days with TN (50 mg/kg).



**Plate 4:** Photograph of a negative Gram stain of the mucous layer, after treatment three days with PAL (50 mg/kg).

*pylori*. This is a *cagA*, *vacA* positive strain which has been widely used satisfactorily in *Helicobacter*-related peptic ulcer research.

We have recently carried out an *in vitro* screening study of the antimicrobial activity against *Helicobacter pylori* (CCUG 39500) and *Campylobacter jejuni*-coli using 69 crude extracts obtained from Cameroonian medicinal plants (Tan et al., unpublished). The *in vitro* antimicrobial actions of the pure compounds used in the present study have also been demonstrated (Tan et al., unpublished). Unfortunately, these results can not be relied on as evidence of *in vivo* activity. Because of the high cost of equipment and instrumentation necessary to work in *in vivo* conditions that conform strictly to the Lausanne criteria of *H. pylori* experimentation, only few laboratories are privileged to work in this domain. For example, 1 – 2 months are needed after inoculation before colonisation with the Sydney strain of *H. pylori* is assessed, and it takes up to 8 months before a histologically-detectable chronic active gastritis develops in mice (Lee et al., 1997). For this reason, it would be of advantage



during massive screening exercises to use a low-cost short-term model that can demonstrate the antimicrobial potencies of new products *in vivo*. A select number of highly active products can then be used as candidates for detailed work involving pathology in collaboration with advanced laboratories.

The *H. pylori* strain used (the CCUG 39500 strain) is a human species that corresponds to the ATCC 43504 and NCTC 11637 strains (CCUG Web site a & b) which are routinely used for *in vitro* work largely due to their ease of cultivation (Best et al., 2003; Hassan et al., 1999; Svenson et al., 2002; Takeshi et al., 2002). Following CCUG instructions, the microbe was successfully revived and maintained in culture with regular sub culturing every 72 hours. All standard microbiological techniques for culture and assessment of colonisation were observed. However, the results obtained showed that the microbe was able to colonise the stomach mucous layer for up to 15 days maximum in contrast to the long-term colonisation usually obtained with the SS1 strain. Thus, the CCUG strain, although a human pathogen, is unable to withstand the mouse defence mechanism beyond two weeks and therefore cannot survive long enough in the mouse to induce pathological gastritis. However, the length of time the microbe survived in the mouse offers a window of opportunity to test the antimicrobial effect of anti-*Helicobacter* products under *in vivo* conditions. Thus, the decision to dose the animals with the antimicrobial products from days 2 to 4 post inoculation was based on the certainty of effective presence of the pathogen in the mucous layer within this period as shown by the Gram stain, urease and culture tests (Table 1). The SS1 strain can be left for up to one week after inoculation after which a two-week antimicrobial therapy is conducted (Lee et al., 1997). Thus, *H. pylori* CCUG-39500 is a human gastric mucosa-adapted strain of *H. pylori*, that is not adapted to mice for use in the study of the mechanism of chronic gastritis and gastric malignancy associated with *H. pylori* infection and to understand the pathogenesis of the infection. It may be necessary therefore to conduct pilot experiments order to ascertain the exact window of the short infection period that can be exploited for antimicrobial assessment using the CCUG-39500 strain. Since complete clearance of a standard *H. pylori* strain from the stomach was obtained during the treatment period, further quantitative analysis was not employed in order to detect its presence. However, it is suggested that in using the present model, quantitative evaluation, especially for new products showing partial clearance, should be carried out.

Important insights into bacterial factors governing the colonisation as well as the host factors associated with the development of pathology have been provided by several animal models (Danon et al. 1995; Enno et al., 1995; Fox et al., 1995; Sakigami et al., 1996; Lee et al., 1997; Krakowka et al., 1998; Lee, 1998). For the *in vivo* assessment of anti *Helicobacter* compounds, mice and Mongolian gerbils are most often used (Kanamaru et al., 2001; Sgouras et al., 2004). However, there is no animal model of *H. pylori* infection that exactly mimics the human disease (Lee, 1998).

The *in vivo* antimicrobial tests carried out using this short-term mouse model confirm the activity of metronidazole as an antibiotic of choice in *H. pylori* eradication therapy. The results show that in addition to the *in vitro* activity of PAL and TN, these new compounds also have *in vivo* antibacterial effects. The gastric anti-secretory activity of TN similar to that of H<sub>2</sub> receptor blockers of histamine has been shown, and the ulcer healing properties of these compounds are associated with an enhancement of

gastric mucus production (Tan et al., 2000; Tan and Nyasse, 2000). In combination with ranitidine, **PAL** and **TN** have also exhibited potentiating and synergistic antisecretory effects, respectively (Tan et al., 2002). The combined ulcer healing and antimicrobial potencies of these compounds enlist them as possible future candidates for the formulation of monotherapy antiulcer regimens with improved patient compliance.

Positive results obtained from *in vitro* screening of extracts for anti *Helicobacter* activity do not constitute absolute proof of eventual *in vivo* efficacy. Thus, in spite of the obvious limitation of the present model which consist in the inability of the CCUG 39500 strain to colonize the mouse gastric mucous layer beyond two weeks, it nevertheless offers the opportunity for the short-term rapid screening of new plant products under *in vivo* conditions. Possible candidates for more detailed investigations can thus be selected at low cost.

## Acknowledgements

This research was supported by the International Foundation for Science, Stockholm, Sweden, and the United Nations University (UNU), Tokyo, Japan, through grant F/2882-2 awarded to Dr Paul V. Tan and IFS/OPCN grant F2626-3 awarded to Prof. B. Nyasse.

## References

1. Beales, Ian L.P. (2001). Efficacy of *Helicobacter pylori* eradication therapies: a single centre observational study. *BMC Gastroenterology*: 1:1-9.
2. Best L. M., Haldane D. J. M., Keelan M., Taylor D. E., Thomson A. B. R., Loo V., Fallone C. A., Lun P., Smaill F. M., Hunt R., Gaudreau C., Kenedy J., Alfa M., Pelletier R., Veldhuyzen van Zanten S. J. O. (2003). Multilaboratory comparison of proficiencies in susceptibility testing of *Helicobacter pylori* and correlation between agar dilution and E Test methods. *Antimicrob Agents Chemother.* **47**(10): 3138 – 3144.
3. Blaser N. J. (1997). Not all *Helicobacter pylori* strains are created equal: should all be eliminated? *Lancet* **349**: 1020 – 1022.
4. CCUG Web site (a). Microaerophilic growth conditions for most *Helicobacters*. <http://www.ccug.se/default.cfm?navID=14> (27 February 2006, date last accessed).
5. CCUG Web site (b). CCUG database selected: Microorganisms (strains). [http://www.ccug.se/default.cfm?page=search\\_record.cfm&id=12610&db=mc](http://www.ccug.se/default.cfm?page=search_record.cfm&id=12610&db=mc) (27 February 2006, date last accessed).
6. Cheesbrough M. (2000). Microbiological tests. In *District Laboratory Practice in Tropical Countries Part 2* Cheesbrough M; editor. Cambridge Low Price Edition. p. 45 -157.
7. Danon J. S., O'Rourke L. L., Moss D. N., Lee A. (1995). The importance of local acid production in the distribution of *Helicobacter felis* in mouse stomach. *Gastroenterology*. **108**: 1386 – 1395.

8. DeCross A. J., Marshall B. J. (1993). The role of *Helicobacter pylori* in acid-peptic disease. *Am. J. Med. Sci.* **306**: 381 – 391.
9. Dunn B. E., Cohen H., Blaser M. J. (1997). *Helicobacter pylori*. *Clin. Microbiol. Rev.* **10**(4):720–741
10. Enno A., O'Rourke J. L., Howlett R. C., Andrew J., Dixon M. F., Lee A. (1995). MALToma-like lesion in murine gastric mucosa after-long-term infection with *Helicobacter felis*. A mouse model of *Helicobacter pylori* – induced gastric lymphoma. *Am. J. Pathol.* **147**(1): 217 – 222.
11. Fauchere J. L. (1999). Bacteriological characteristics and diagnosis of *Helicobacter pylori* Laborama. **6**: 10–14.
12. Fox G. J., Batchelder M., Marini R., Yan L., Handt L., Li x., Shames B., Hayward A., Campbell J., Murphy J. C. (1995). *Helicobacter pylori*-induced gastritis in domestic cats. *Infect. Immun.* **63**(7): 2674 – 2681.
13. Gibson J. R., Saunders N. A., Burke B., Owen R. J. (1999). Novel method for rapid determination of Clarithromycin sensitivity in *Helicobacter pylori*. *J. Clin. Microbiol.* **37** (11): 3746 – 3748
14. Graham D. Y. (1997). *Helicobacter pylori* infection in the pathogenesis of duodenal ulcer and gastric cancer: a model. *Gastroenterology* **113**: 1983 – 1991.
15. Haas, C.E., Nix, D.E., Schentag, J.J. (1990). *In vitro* selection of resistant *Helicobacter pylori*. *Antimicrob. Agents Chemother.* **34**: 1637–1640.
16. Hassan J. I., Stark M. R., Greenman, J., Millar, R. M. (1999). Activity of  $\beta$ -Lactams and Macrolides against *Helicobacter pylori*. *Antimicrob Agents Chemother.* **43**(6): 1387–1392.
17. Hentschel E. G., Brandstatter B., Dragosics A. M., Hirschl H., Nemec K., Schutze M., Wurzer H.( 1993). Effet of ranitidine and Amoxicillin plus Metronidazole on the eradication of *H. pylori* and recurrence of duodenal ulcer. *N. Engl. J. Med.* **328**: 308–312.
18. Jenks P. J., Labigne A., Ferrero R. L. (1999). Exposure to Metronidazole In Vivo Readily Induces Resistance in *Helicobacter pylori* and Reduces the Efficacy of Eradication Therapy in Mice. *Antimicrob. Agents Chemother.* **43**(4): 777–781.
19. Kanamaru T., Nakano Y., Toyoda Y., Ken-Ichiro M., Mayumi T., Tomoko K., Masafumi N. (2001). *In Vitro* and *In Vivo* Antibacterial Activities of TAK-083, an Agent for Treatment of *Helicobacter pylori* Infection. *Antimicrob Agents Chemother.* **45** (9): 2455–2459.
20. Kato M., Yamaoka Y., Jae J. K., Reddy R., Asaka M., Kashima K., Osato M. S., El-Zaatari K. A. F., Graham Y. D. Kwon H. D. (2000). Regional Differences in Metronidazole Resistance and Increasing Clarithromycin Resistance among *Helicobacter pylori* Isolates from Japan. *Antimicrob Agents Chemother.* **44**(8): 2214–2216.
21. Krakowka S., Eaton K. A. and Leunk D. R. (1998). Antimicrobial therapies for *Helicobacter pylori* Infection in Gnotobiotic piglets. *Antimicrob Agents Chemother.* **42**(7): 1549-1554.
22. Lee A. O'Rourke J., De Ungria M. C., Bronwyn R., Daskalopoulos G., Dixon F. M. (1997). A standardized mouse model of *Helicobacter pylori* infection: Introducing the Sydney strain. *Gastroenterology.* **112**(4): 1386 – 1397.
23. Lee A. (1998). Animal models for host-pathogen interaction studies. *Brit. Med bull.* **54** (1): 163 – 173.

24. Loughlin M. F., Ala'Aldeen D. A., Jenks J. P. (2003). Monotherapy with mastic does not eradicate *Helicobacter pylori* infection from mice. J. Antimicrobial Chemother. **51**: 367 – 371.
25. Mahady G. B., Pendland S. L., Yun S. G., Zhi-Zhen L., Stoia A. (2003a). Ginger (*Zingiber Officinale Roscoe*) and the Ginerol Inhibit the growth of cag A<sup>+</sup> Strains of *helicobacter pylori*. Anticancer Research: **23**: 3699 – 3702.
26. Mahady G. B., Pendland S. L., Stoia A., Chadwick R. L. (2003b). In vitro susceptibility of *Helicobacter pylori* to Isoquinoline Alkaloids from *Sanguinaria canadensis* and *Hydrastis canadensis*. Phytother. Res. **17**: 217 – 221.
27. Marone P., Bono L., Leone E., Bona S., Carretto E. and Perversi, L. (2001). Bactericidal activity of *Pistacia lentiscus* mastic gum against *Helicobacter pylori*. J. Chemother. **13**: 611 – 614.
28. Nataliya I. B., Yoon Y. J., Kim K. (2000). Inhibition of *Helicobacter pylori* Hemagglutination by polysaccharide fractions from the roots of Panax ginseng. Planta Medica. **66**: 217 – 220.
29. Niyaz A. and Sechi A. L. (2005). *Helicobacter pylori* and gastroduodenal pathology: New threads of the old friend. An Clin. Microbiol. Antimicrob. **4** (1): 1 – 10.
30. Okamoto T., Yoshiyama H., Nakazawa T., In-Dal P., Myung-Woong C., Yanai H., Okita K., Shirai M. (2002). A change in PBP1 is involved in amoxicillin resistance of clinical isolates of *Helicobacter pylori*. Antimicrob Agents Chemother. **50**: 849 – 856.
31. Radcliff F.J., Chen M., Lee A. (1996). Protective immunization against *Helicobacter* stimulates long-term immunity. Vaccine. **4**(8):780-784.
32. Sakagami T., Dixon M, O'Rourke J., Howlett R., Alderuccio F., Vella J., Shimoyama T., Lee A. (1996). Atrophic gastric changes in both *Helicobacter felis* and *Helicobacter pylori* infected mice are host dependent and separate from antral gastritis. GUT. **39**(5): 369 – 348.
33. Sgouras D., Maragkoudakis P., Petraki K., Martinez-Gonzalez B., Eriotou E., Michopoulos S., Kalantzopoulos G., Tsakalidou E. and Mentis A. (2004). In Vitro and In Vivo Inhibition of *Helicobacter pylori* by *Lactobacillus casei* Strain Shirota Ap. Environ. Microbiol. **70** (1): 548-526.
34. Sjöström J. E., Kühler T., Larsson H. (1997). Basis for the Selective Antibacterial Activity In Vitro of Proton Pump Inhibitors against *Helicobacter* spp. Antimicrob Agents Chemother. **41**(8): 1797–1801.
35. Skirrow M.B. (1992). *Campylobacter* and *Helicobacter* enteritis; gastritis in *Medical Microbiology* Greenwood *et al.*, editors. 14<sup>th</sup> edition; ELBS edition. p. 353–361.
36. Svensson M., Ström M., Nilson M., Sörberg M., Nilson L. E. (2002). Pharmacodynamic effects of Nitimidazoles alone and in combination with Clarithromycin on *Helicobacter pylori*. Antimicrob Agents Chemother. **46**(7): 2244 – 2248.
37. Takeshi Okamoto, Hironori Yoshiyama, Teruko Nakazawa, In-Dal Park, Myung-Woong Chang, Hideo Yanai, Kiwamu Okita, Mutsunori Shirai. (2002). A change in PBP1 is involved in amoxicillin resistance of clinical isolates of *Helicobacter pylori*. J. Antimicrob. Chemother. **50**: 849–856
38. Tan, P. V., Nyasse, B., Enow-Orock, G.E., Wafo, P., Forcha, E.A. (2000). Prophylactic and healing properties of a new anti-ulcer compound from *Enantia chlorantha* in rats. Phytomedicine **7**(4): 291-296.

39. Tan, P.V., Nyasse, B., Dimo, T., Wafo, P., Akahkuh, B.T. (2002). Synergistic and potentiating effects of ranitidine and two new anti-ulcer compounds from *Enantia chlorantha* and *Voacanga africana* in experimental animal models. *Pharmazie* **57**(6): 409-412.
40. Tan, P. V., Nyasse, B. (2000). Anti ulcer compound from *Voacanga africana* with possible histamine H<sub>2</sub> receptor blocking activity. *Phytomedicine* **7**(6): 509 –515.
41. Van Doorn, H.Y., Nouhan, N., Verschuuren, A., Vreede, R., Herbink, P., Ponjee, G., Van Krimpen, K., Blankenburg, R., Scherpenisse, J., Quint, W. (2000). The efficacy of laboratory diagnosis of *Helicobacter pylori* infection in gastric biopsy specimens is related to bacterial density and *vacA*, *cagA*, and *iceA* genotypes: *J. Clin. Microbiol.* **38**:13-17.
42. Wafo, P., Nyasse, B., Fontaine, C. A. (1999). 7,8-dihydro-8- hydroxypalmatine from *Enantia chlorantha*. *Phytochemistry*. **50**: 279-281.
43. Walsh J. H., Peterson W. L. (1995). The treatment of *Helicobacter pylori* infection in the management of peptic ulcer disease. *N. Engl. J. Med.* **333**: 984 – 991.
44. Yee. Y. K., Koo M. W. (2000). Anti-*Helicobacter pylori* of Chinese tea: *In vitro* study. *Aliment. Pharmacol. Ther.* **14**:615 – 618.